The development of cancer is accompanied by a change in the composition of a sugar molecule called chondroitin sulfate. This sugar molecule becomes unusually long and heavily sulfated. For years, VAR2 has pursued the development of cancer therapeutics targeting this secondary modification called oncofetal chondroitin sulfate. But until recently, the known difficulties in generating antibodies […]
The development of CTC-derived models specific to PDAC has remained challenging due to the limited number of CTCs retrieved from patients’ samples. In work led by our collaborators, we demonstrated that our proprietary recombinant VAR2CSA, which specifically binds oncofetal chondroitin sulfate, retrieved more live CTCs than single antibodies for traditional CTC biomarkers (EpCAM, CD7, […]
Our website only uses strictly necessary cookies. Please consult our Privacy Policy for additional information on how we process your data.